Mereo BioPharma Group plc
MREO
$2.17
-$0.08-3.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.26% | -34.47% | -79.15% | -46.79% | -51.43% |
| Total Depreciation and Amortization | -24.11% | 2.65% | -2.34% | 2.54% | 13.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.12% | 104.35% | 39.47% | 9.41% | 437.59% |
| Change in Net Operating Assets | 97.00% | -126.06% | 117.95% | 76.84% | -97.32% |
| Cash from Operations | -8.30% | -64.39% | -66.90% | -55.38% | -10.13% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 57.08% | 57.29% | -66.83% | -5,823.73% |
| Cash from Investing | 97.14% | 54.22% | 54.43% | -66.83% | -5,582.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -98.96% | -99.17% | 309.19% | 305.00% | 305.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 70.60% | -14.11% | -106.76% | -92.12% | -86.38% |
| Cash from Financing | -99.46% | -100.63% | 484.08% | 478.79% | 459.92% |
| Foreign Exchange rate Adjustments | -75.75% | 353.98% | -48.80% | -108.27% | 151.10% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -276.87% | -190.84% | 224.00% | 215.05% | 173.47% |